Bridgeway Hospice 354 Corporate Center Court, Stockbridge, GA, 30281 | |
(678) 583-2269 |
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
Name | Bridgeway Hospice |
---|---|
Location | 354 Corporate Center Court, Stockbridge, Georgia |
Hospice ID | 111734 |
Category | Freestanding Hospice |
Ownership Type | Proprietary - Corporation |
Profit Type | FOR PROFIT |
SSA county code | 591 |
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
NPI Number | 1043410616 |
Organization Name | Bridgeway Hospice, Inc. |
Address | 1041 Thurman Rd Stockbridge, Georgia, 30281 |
Phone Number | (770)389-8784 |
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
NPI Number | 1043632334 |
Organization Name | Peachtree Hospice Of Georgia, Llc |
Address | 354 Corporate Center Ct Stockbridge, Georgia, 30281 |
Phone Number | (678)583-2269 |
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
Quality Measure | Provider Score | National Score |
---|---|---|
Patients or caregivers who were asked about treatment preferences like hospitalization and resuscitation at the beginning of hospice care | 96.5 | 98.3 |
Patients or caregivers who were asked about their beliefs and values at the beginning of hospice care | 47.9 | 93.6 |
Patients who were checked for pain at the beginning of hospice care | 66.0 | 93.9 |
Patients who got a timely and thorough pain assessment when pain was identified as a problem | 55.4 | 77.7 |
Patients who were checked for shortness of breath at the beginning of hospice care | 97.4 | 97.3 |
Patients who got timely treatment for shortness of breath | 98.6 | 94.6 |
Patients taking opioid pain medication who were offered care for constipation | 97.6 | 93.3 |
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
Home Health Aides | 21 |
Counselors | 4 |
Licensed Practical or Vocational Nurses | 3 |
Medical Social Workers | 3 |
Physicians | 3 |
Registered Nurses | 18 |
Other Personnel | 12 |
Total Employees | 64 |
---|
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
Others | 16 |
Total Volunteers | 16 |
---|
News Archive
A large, international study published Online First in The Lancet reveals alarming levels of tuberculosis (TB) that are resistant to both first-line and second-line drugs. The findings show high prevalence of resistance to at least one second-line drug (43.7%) among multidrug-resistant (MDR) TB patients from eight countries in Africa, Asia, Europe, and Latin America. Worse still, the study found higher than expected overall levels of extensively drug-resistant (XDR) TB.
GenVec, Inc. (Nasdaq: GNVC) announced today that it has received a Phase 2 Small Business Innovation and Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) to support the development of GenVec's vector production technology.
A new study, scheduled to appear in the May 1 edition of Environmental Science & Technology, a peer-reviewed journal of the American Chemical Society, the world's largest scientific society, suggests that current regulations for environmental remediation are inadequate to deal with a dirty bomb attack.
According to trials, a new obesity drug, Tesofensine, which may be launched on the world market in a few years, can produce weight loss twice that of currently approved obesity drugs. The Danish company Neurosearch and a number of researchers at the Faculty of Life Sciences at University of Copenhagen are behind the promising findings.
By reformulating the common cancer drug imatinib (Gleevec), researchers have eliminated morphine tolerance in rats - an important step toward improving the effectiveness of chronic pain management in patients, according to researchers at The University of Texas MD Anderson Cancer Center.
› Verified 9 days ago
Gentiva Hospice Location: 216 Business Center Drive, Stockbridge, Georgia, 30281 Phone: (678) 583-2269 |
Heartland Hospice Services Location: 827 Fairways Court Suite 200, Stockbridge, Georgia, 30281 Phone: (678) 583-2269 |
Providence Hospice, Inc Location: 100 Corporate Center Drive Lower Level, Stockbridge, Georgia, 30281 Phone: (678) 583-2269 |
Bridgeway Hospice Location: 354 Corporate Center Court, Stockbridge, Georgia, 30281 Phone: (678) 583-2269 |